This document was created based on the satellite symposium entitled "Evolution of the Individualized Treatment Landscape for Advanced NSCLC." This symposium was held during the IASLC Asia Pacific Lung Cancer Conference (APLCC 2016).
These documents were produced through satellite symposium entitled "Individualizing the Treatment of Advanced NSCLC," held at the IASLC 7th Latin American Conference on Lung Cancer (LALCA 2016).
DENVER – The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.
DENVER – Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.
DENVER – The timing of surgery after neoadjuvant chemoradiation in patients with stage IIIA non-small cell lung cancer (NSCLC) affects the overall survival of patients receiving trimodality therapy.
DENVER – The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.